Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 1Solid Tumor, Adult 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 39Paclitaxel 35Radiosurgery 30Gemcitabine 30Carboplatin 30Cisplatin 23Irinotecan 22Ipilimumab 22Cyclophosphamide 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14atezolizumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × amivantamab × 1 year × Clear all
NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡